Patients with metastatic non-small cell lung cancer who received a combined therapy of tremelimumab, durvalumab and chemotherapy experienced longer overall survival compared with those who received chemotherapy alone, regardless ...
Aug 9, 2022
0
2
A research team, comprised of Associate Professor Tomonari Sumi of the Research Institute for Interdisciplinary Science at Okayama University and Associate Professor Kouji Harada of the Center for IT-based Education (CITE) ...
Aug 3, 2022
0
4
No other infectious disease has killed more people than tuberculosis. Currently, only one vaccine is available to prevent severe courses: Bacillus Calmette Guérin (BCG). However, it is not equally effective against all types ...
Aug 2, 2022
0
2680
Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG—with promising ...
Jul 28, 2022
0
101
The U.S. Centers for Disease Control and Prevention on Tuesday gave its blessing for the emergency use of Novavax's COVID-19 vaccine, the fourth coronavirus shot to be approved in the United States.
Jul 20, 2022
0
16
Coinfection of SARS-CoV-2 and influenza A virus changes neither the trajectory, nor the severity of influenza A virus, regardless of timing. But should the host contract influenza A virus first, the response to that infection ...
Jul 12, 2022
0
5
Even before carbohydrates reach the bloodstream, the very sight and smell of a meal trigger the release of insulin. For the first time, researchers from the University of Basel and University Hospital Basel have shown that ...
Jun 30, 2022
0
161
While COVID-19 vaccines continue to be highly effective at preventing hospitalization and death, it has become clear that the protection offered by the current vaccines wanes over time. This necessitates the use of booster ...
Jun 28, 2022
0
3
Colorectal, pancreatic, esophageal and stomach cancers—some of the deadliest kinds of cancer—have high recurrence rates where the cancer comes back even after successful surgery or radiation treatment.
Jun 23, 2022
0
891
Skyrizi (risankizumab-rzaa), an interleukin-23 inhibitor, has received U.S. Food and Drug Administration approval to treat moderately to severely active Crohn disease (CD) in adults, according to AbbVie.
Jun 20, 2022
0
4
